Particle.news
Download on the App Store
6 ARTICLES
·
yesterday

NICE Approves Alyftrek, Extending Modulator Treatment to 95% of Cystic Fibrosis Patients

Following the MHRA’s March clearance, NHS England will roll out the once-daily triple therapy to patients aged six or older, including those with rare CF mutations previously excluded.

image: ©SARINYAPINNGAM iStock
Image
Image
Image

Overview

  • NICE has recommended NHS funding of Alyftrek for cystic fibrosis patients aged six or older as of July 2025.
  • NHS England says 95% of people with CF in England will now be eligible, unlocking access for those with rare CFTR mutations for the first time.
  • The MHRA authorised the triple combination in March, and clinical trials have shown it to match existing treatments in improving and maintaining lung function.
  • Officials say the once-daily tablet will reduce the burden of complex regimens and could transform life expectancy and daily quality of life.
  • The approval caps years of cost-effectiveness scrutiny by NICE and follows NHS England’s long-term access deals secured in mid-2024 for earlier modulators.